Study met primary endpoint, demonstrating a higher proportion of sustained platelet response with VYVGART treatment compared to placebo ; responders observed across patient types regardless of prior. | May 5, 2022
April 28, 2022Breda, the Netherlands – argenx , a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will. | April 28, 2022